In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
在BCR- ABL阴性的骨髓增殖性疾病的发病机制中,JAK2V 617 F点突变的发现是一个重大的突破。
In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
在BCR- ABL阴性的骨髓增殖性疾病的发病机制中,JAK2V 617 F点突变的发现是一个重大的突破。
应用推荐